We describe the development and validation of a Iabeled-hapten competitive immunoassay for determining total estrone in serum. For the hapten tracer we use the 6a-biotinylated estrone derivative, 3-hydroxyestra-1,3,5(1 0)-trien-1 7-one 6a-N-(e-biotinyl)aminocaproamide (Bio-E1 
Materials and Methods

Reagents
Chemicals.
El Germany. The '251-labeled direct El RIA was obtained from DSL, Webster, TX.
Reagent solutions.
The assay buffer consisted of 1 
Preparation of Blo-El
Bio-El was synthesized as described elsewhere (15).
In brief, El was oxidized at position 6 with Cr03, followed by a reductive amination at the same position. Cross-reactivity. Cross-reactivity was calculated according to Abraham (16) and expressed as the ratio of the apparent El concentration to the added concentration of cross-reacting steroid at 50% binding of a nearly El-free serum sample.
Serum Specimens
Blood was taken from apparently healthy men (n = 44; ages 19-55) and premenopausal women (42 nonpregnant, ages 20-44; 11 pregnant, ages 20-38); all were assumed to be free from any acute or chronic disease on the basis of a medical and clinical chemistry examination.
The women with polycystic ovary syndrome (PCOS; n = 18, ages 26-35) were diagnosed by the usual clinical criteria.
The sera were stored at -70#{176}C after centrifugation until assayed. Before assay, 300 L of serum sample was pipetted onto a C18 cartridge that had been primed with 1 mL of methanol and 1 mL of H20. After washing with 1 mL of H20, the endogenous steroids were eluted with 1 mL of dichloromethane.
After removal of the organic solvent, the extract was redissolved in 300 L of assay buffer, incubated for 60 miii at 37#{176}C, and centrifuged at l000g; then the specimens were ready for assay. 
Results
Preparation of biotinylated El tracer and displacement experiments.
A scheme of the five-step synthesis is given in Fig. 1 . As a tracer we used the 6a-epimer of We determined the linearity of dilutions for six sera with high endogenous El content. Results are shown in Fig. 3 .
The lowest El concentration significantly different from zero was 2.7 fmol/well. This is equivalent to a serum El concentration of 55 pmol/L. El (pmol/L) RIA Table 3 . Because an extraction step was included, no interferences were observed in the measurements of hemolytic sera, sera containing increased lipoproteins, or sera from patients with either hyperbilirubinemia or monoclonal hypergammaglobulinemia (data not shown).
Measurements of El serum concentrations in adults.
The mean values, SD, and 95% range of El concentrations in sera of healthy men, healthy premenopausal women (prefollicular, penovulatory, and postovulatory phases), pregnant women (2nd and 3rd trimesters), and women with PCOS are given in Table 4 .
Intermet hod comparison. We compared the results for El concentrations in 143 sera with a commercially available 1251-RIA (DSL). This nonextraction assay includes a rabbit anti-El antibody together with a precipitating goat anti-rabbit antiserum in PEG buffer. 
Discussion
The development of immunoassay techniques has generated numerous sensitive and specific methods for the measurement of low-and high-molecular-mass analytes.
Nonisotopic immunoassay procedures, as sensitive and specific as RIA methods, have enabled a versatile and reliable application in endocrinological diagnoses.
The wide availability of these assays, together with an ease of handling and low costs, accommodates the monitoring of hormonal status in endocrine diseases.
The properties of a competitive enzyme immunoassay for steroids largely depend on the attachment point of the respective steroid, both for coupling to the carrier protein in antibody production and for inserting a prosthetic enzyme reporter group into the steroid in tracer synthesis.
Thus, two points must be considered in detail: the alteration of the key structural determinants of the steroid, and the orientation and chemical nature of the linkage. Minimal alteration of the labeled steroid leads to an improved specificity of the immunoassay, whereas optimal structure design and orientation of the bridge are associated with both a good fitting of the steroid into the binding pocket of the antibody and a low antigenicity, preventing bridge binding of the antibody, to improve the assay's sensitivity. We therefore synthesized a new El tracer to insert the label of the hapten tracer in position 6 
